


The Fund aims to achieve a total return.
| Name | % Net Assets |
|---|---|
| Bundesschatzanweisungen 0.25 13/12/2013 | 3.0% |
| United Kingdom Gilt 4.25 07/12/2040 | 1.8% |
| United States Treasury Note/Bond 3.75 15/11/2018 | 1.2% |
| United Kingdom Gilt 5.25 07/06/2012 | 0.9% |
| GlaxoSmithKline PLC | 0.9% |
| Royal Dutch Shell PLC | 0.8% |
| United Kingdom Gilt Inflation Linked 2.5 26/07/2016 | 0.8% |
| AstraZeneca PLC | 0.7% |
| SNS Bank NV 1.735 27/04/2012 | 0.7% |
| United Kingdom Gilt 3.75 07/09/2019 | 0.7% |
| Key | % Net Assets |
|---|---|
| 3.0% | |
| 1.8% | |
| 1.2% | |
| 0.9% | |
| 93.1% |
| Date | 09-Apr-2021 |
|---|---|
| Bid | 108.40p |
| Offer | 108.40p |
| Currency | GBP |
| Change | 0.000p |
| % | n/a |
| YTD change | 108.40p |
| YTD % | n/a |
| Fund Inception | 16/09/2002 |
|---|---|
| Fund Manager | Quentin Fitzsimmons |
| TER | 1.26 (30-Mar-2012) |
| Minimum Investment | |
|---|---|
| Initial | £2000 |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | 3.75% |
| Annual Mang't | 0.25% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.00 |
| Sharpe ratio | 0.11 |
You are here: research